Marilyne Labrie

May 1, 2024 | jci.org | Gordon Mills |Marilyne Labrie |Kyle Vaccaro |Aaron N. Hata

AbstractTargeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro- or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins.